摘要
目的:探讨卵巢癌患者血清CA125、TSGF、SF联检中水平及临床意义。方法:采用放免法和生化法对32例卵巢癌患者进行了血清CA125、TSGF、SF检测,并与30例正常健康人作比较。结果:卵巢癌患者血清中CA125、TSGF、SF含量非常显著地高于正常人组(P<0.01),经手术治疗后3个月,其含量显著下降,与正常人比较,无显著性差异(P>0.05)。结论:检测卵巢癌患者血清中CA125、TSGF、SF含量对临床的诊断和预后判断具有重要的临床价值。
Objective To investigate the clinical significance of combined determination of serum CA125, TSGF and SF levels in patients with ovarian cancer, Methods Serum CA125, SF levels measured with RIA and TSGF measured with biochemistry in 32 patients with ovarian cancer and 30 controls. Results The serum CA125, TSGF and SF levels in the patients were significantly higher than those in controls （P 〈0.01 ）. Three months after operation serum CA125, TSGF and SF levels markedly dropped with significant difference from those in controls （P 〉 0.05 ）. Conclusion Detection of serum CA125, TSGF and SF levels in patients with ovarian cancer was helpful for diagnosis and outcome prediction.
出处
《放射免疫学杂志》
CAS
2005年第4期265-267,共3页
Journal of Radioimmanology
